Skip to main
VCYT
VCYT logo

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 47%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

Veracyte Inc. demonstrated strong growth in genomic test volume, achieving a 25% increase year-over-year, highlighted by an impressive 45% growth in urology tests from the Decipher platform. The company reported an adjusted EBITDA margin improvement of 690 basis points compared to the previous year, alongside a significant rise in testing revenue to $112.2 million, an increase of 24%. Additionally, management's guidance for an adjusted EBITDA margin of approximately 21.6% for 2025, elevated by ongoing adoption among existing customers and the introduction of larger new accounts, indicates a robust operational outlook.

Bears say

Veracyte Inc. is facing a negative outlook primarily due to slower-than-expected growth rates for its key cancer diagnostic tests, Decipher and Afirma, alongside anticipated weaker margin performance and earnings projections. Revenue growth has decelerated from 29% in 3Q24 to 21% in 4Q24, coupled with a slight decline in revenue per test, which fell approximately 1% year-over-year. Additionally, there are potential headwinds related to an exit from the VCYT subsidiary, which may impact consensus revenue estimates for 2025, thus raising concerns about sustained financial performance.

Veracyte (VCYT) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 47% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 15 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.